

**REMARKS**


In the Notice to Comply, the Examiner indicated that claims 87 and 88 recite amino acid sequences which were not assigned a sequence identification number. The amino acid sequences SEVNLDAEFR and EVKMDAEF were listed in the sequence listing as originally filed as SEQ ID NOS: 63 and 67, respectively. In the foregoing amendment these sequence identification number were added to claims 87 and 88. These amendments do not add new matter to the application.

A substitute sequence listing is submitted herewith to put the application in better compliance with the sequence rules set out in 37 C.F.R. § 1.821-1.825. The sequence P2, P1, P1', P2' at page 12, line 19, was not previously assigned a sequence identification number. Although it may not be necessary, the substitute sequence listing includes SEQ ID NO: 74 representing the sequence for P2, P1, P1', P2'. This sequence is defined in the specification at page 12, line 18-20 and therefore adds no new matter. The specification is amended at page 12 to include an appropriate cross-reference to P2, P1, P1', P2' as SEQ ID NO: 74. In addition, the identifier <223> defines the peptides of SEQ ID NOS: 62-72 as "synthetic peptides."

Attached hereto as Appendix A is a marked-up version of the changes made to the specification and claims by the current amendment.

Dated: December 30, 2002

Respectfully submitted,

By   
Sharon M. Sintich, Ph.D.

Registration No.: 48,484  
MARSHALL, GERSTEIN & BORUN  
233 S. Wacker Drive, Suite 6300  
Sears Tower  
Chicago, Illinois 60606-6357  
(312) 474-6300

**APPENDIX A**  
**MARKED UP VERSION OF AMENDMENTS TO THE**  
**SPECIFICATION AND CLAIMS**

**RECEIVED**

JAN 10 2003

**IN THE SPECIFICATION**

TECH CENTER 1600/2900

At page 12, line 13:

--In one variation, the cells are collected and the critical peptide is the APP C-terminal peptide created as a result of the  $\beta$  secretase cleavage. In another variation, the supernatant is collected and the critical peptide is soluble APP, where the soluble APP has a C-terminus created by  $\beta$  secretase cleavage. In preferred embodiments, the cells contain any of the nucleic acids or polypeptides described above and the cells are shown to cleave the  $\beta$  secretase site of any peptide having the following peptide structure, P2, P1, P1', P2' (SEQ ID NO: 74, where P2 is K or N, where P1 is M or L, where P1' is D, where P2' is A. [The method of claim 111 where] In one embodiment P2 is K and P1 is M[. The method of claim 112 where] and in another embodiment P2 is N and P1 is L. --

**IN THE CLAIMS**

87. (Amended) A method according to claim 83, wherein the substrate polypeptide of the second composition comprises the amino acid sequence SEVNLDAEFR (SEQ ID NO: 63).

88. (Amended) A method according to claim 83, wherein the substrate polypeptide of the second composition comprises the amino acid sequence EVKMDAEG (SEQ ID NO: 67).